Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: Still a question?

Cancer Treatment Reviews

Volumn 24, Issue 1, 1998, Pages 15-26

  Colleoni, M ^a   Coates, A ^b   Pagani, O ^c   Goldhirsch, A ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Ospedale Beata Vergine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; FLUOXYMESTERONE; GONADORELIN DERIVATIVE; GOSERELIN; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; OCTREOTIDE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OVARIECTOMY; PREMENOPAUSE;

EID: 0031953005     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90068-8     Document Type: Article

References (56)

1. Valagussa P, Bonadonna G, Veronesi U et al. Patterns of relapse and survival following radical mastectomy. Analysis of 761 consecutive patients. Cancer 1978; 41: 1170-1178.
2. Martin DS, Fughan RA. A role of chemotherapy as an adjunct to surgery. Cancer Res 1957; 17: 1098-1101.
3. Fisher R, Ravdin G, Ausman RK et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968; 168: 337-356.
4. Martin DS. Clinical implications of the interrelationship of tumor size and chemotherapeutic response. Ann Surgery 1960; 151: 97-100.
5. Fisher B, Redmond C, Brown A. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981; 305: 1-6.
6. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-410.
7. Early Breast Cancer Trialists' Collaborative Group Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15, 71-85.
8. Baum M, Brinhley DM, Dossett JA et al. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: analysis at eight years by Nolvadex Adjuvant Trial Organization. Br J Cancer 1988; 57: 608-611.
9. Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer. Five-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986; 4: 459-71.
10. Osborne CK. Effects of estrogens and antiestrogens on cell proliferation. Implications for treatment of breast cancer. In: Osborne C K ed, Endocrine Treatment in Breast and Prostate Cancer. Boston: Kluwer, 1988; 11-129.
11. Cavalli F, Pedrazzini A, Martz G. Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer. Eur J Cancer Clin Oncol 1983; 19: 1615-1624.
12. ANZ Breast Cancer Trials Group A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 1986; 4: 186-193.
13. Boccardo, Rubagotti A, Amoroso D et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) Trial. Eur J Cancer 1992; 28: 673-680.
14. Fisher B, Redmond C, Legault-Poisson S et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-18.
15. Goldhirsch A, Gelber RD. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig studies III and IV. Recent Results Cancer Res 1990; 115: 153-162.
16. Rivkin S, Green S, Metch B et al. Adjuvant chemotherapy (CMFVP) vs oophorectomy followed by chemotherapy (OCMFVP) for premenopausal women with Er positive operable breast cancer with positive nodes: A SWOG study. J Clin Oncol 1996; 14: 46-51.
17. Goldhirsch A, Wood WC, Senn HJ et al. Meeting Highlights: International Consensus Panel on the treatment of primary breast cancer. J Nat Cancer Institute 1995; 87: 14-20.
18. The International Breast Cancer Study Group Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breasts cancer patients. J Clin Oncol 1997; 15: 1385-1394.
19. Pritchard KI, Zee B, Paul N et al. Randomized trial of cyclophosphamide, methotrexate and fluorouracil chemotherapy added to tamoxigen as adjuvant chemotherapy in postmenopausal women with node positive and estrogen receptor positive breast cancer: a report from the NCIC. J Clin Oncol 1997; 15: 2302-2311.
20. Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy in lymph node negative estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-1682.
21. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 1997; 127: 380-387.
22. Albain K, Green S, Osborne K, Cobau C et al. for SWOG, ECOG, CALGB, NCCTG, and NCI-Canada. Tamoxifen (T) versus cyclophosphamide, Adriamycin® and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III Intergroup trial (SWOG-8814, INT-0100). Proc Am Soc Clin Oncol 1997; 16: 128.
23. Rivkin SE, Green S, Metch B et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients. A Southwest Oncology Group Study. J Clin Oncol 1994; 12: 2078-2085.
24. Engelsman E, Klijn JC, Rubens RD, Wildiers J et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTIC Breast Cancer Co-operative Group phase III trial (10808). Eur J Cancer 1991 27: 966-970.
25. Gerard J P, Hery M, Gedouin D et al. Postmenopausal patients with node-positive resectable breast cancer: tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control. Preliminary results of a 4-arm randomized trial. Drugs 1993; 45: 60-67.
26. Pearson OH, Hubay CA, Gordon NH et al. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. Cancer 1989; 64: 1819-1823.
27. Hupperets PSGJ, Wilòs J, Volovis L et al. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and fluorouracil (CAF) with or without medroxyprogesterone acetate for node positive breast cancer patients. Ann Oncol 1993; 4: 301-305.
28. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone P. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An ECOG trial. Cancer 1990; 65: 200-206.
29. Taylor SG, Knuiman MW, Sleeper LA et al. Six-year results of the Eastern Cooperative Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with nodepositive breast cancer. J Clin Oncol 1989; 7: 879-889.
30. Schumacher M, Bastert G, Bojar H et al. Randomized 2×2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol 1994; 12: 2086-93.
31. Kaufmann M, Jonat W, Abel U et al. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/ cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 1993 11: 454-460.
32. Bianco AR, De Placido S, Gallo C et al. Adjuvant therapy with tamoxifen in operable breast cancer: 10 year results of the Naples (GUN) Study. Lancet 1988; 2: 1095-1099.
33. Fisher, Carbone P, Economou SG et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975 292: 117-122.
34. Dombernowsky P, Brincker H, Hansen M et al. Adjuvant chemotherapy of premenopausal and postmenopausal risk breast cancer patients. Acta Oncol 1988; 27: 291-296.
35. Crowe JP, Gordon NH, Shenk RR, Soegiarso RW, Hubay CA. Short term tamoxifen plus chemotherapy: superior results in node-positive breast cancer. Surgery 1990; 10: 619-627.
36. Ingle JN, Everson LK, Wieand HS, Martin K et al. Randomized trial of observation versus adjuvant therapy with CMGp with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol 1988; 6: 1388-1396.
37. Rutqvist LE, Cedermark B, Gla U et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990; 66: 89-96.
38. Hubay CA, Pearson OH, Manni A, Gordon NH, McGuire WL. Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6 year result. J Steroid Biochem 1985; 23: 1147-1150.
39. Mauriac L, Durand M, Chauvergne J, Bonichon F, Avril A. Adjuvant trial for stage II receptor-positive breast cancer: CMF vs CMF+tamoxifen in a single centre. Breast Cancer Res Treat 1988; 11: 179-186.
40. Blomqvist C, Tiusanen K, Elomaa I, Rissanen P et al. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide, doxorubicin ftorafur and tamoxifen in stage II breast cancer. Long term follow up results of a randomized trial. Br J Cancer 1992; 66: 1171-1176.
41. Ingle JN, Everson L, Wieand S et al. Randomized trial to evaluate the addition of tamoxifen to CMFp adjuvant therapy in premenopausal women with node positive breast cancer. Cancer 1989; 63: 1257-1264.
42. Pannuti F, Martoni A, Cilenti G et al. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. Eur J Cancer 1988; 24: 423-429.
43. Ludwig Breast Cancer Study Group A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985; 45: 4454-4459.
44. Fisher B, Sherman B, Rockette H et al. L-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of DFS with depression of ovarian function. Cancer 1979; 44: 847-857.
45. Goldhirsch A, Gelber R. Adjuvant treatment for early breast cancer: the Ludwig Breast Cancer Studies. NCI Monogr 1986; 1: 55-70.
46. Rossi A, Bonadonna G, Tancini G et al. Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan. In: Mouridsen, HT, Palshof T, eds. Breast Cancer - Experimental and Clinical Aspects. Oxford: Pergamon, 1980; 149-156.
47. Greensberg DA, Carpenter CL, Messing RO. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res 1987; 47: 70-76.
48. Berman E, Adams M, Duigou-Ostendorf R et al. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 1991; 77: 818-822.
49. Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother Pharmacol 1988; 22: 147-152.
50. Smith G, Henderson IC. New treatments for breast cancer. Sem Oncol 1996; 23: 506-508.
51. Goldhirsch A, Gelber RD, Castiglione M et al. Present and future project of the International Breast Cancer Study Group. Cancer 1994; 74: 1139-1149.
52. Muss HB, Thor AD, Berry D et al. C-erbB2 expression and response to adjuvant therapy in women with node positive early breast cancer. New Engl J Med 1994; 330: 1260-1266.
53. Wright C, Nicholson S, Angus B et al. Relationship between c-erb B2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-121.
54. Lowe S, Ruley H, Jacks T et al. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
55. Hietanem P, Blomqvist C, Wasenius V-M et al. Do DNA ploidy and S-phase fraction in primary tumor predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 1995; 71: 1029-1032.
56. Makris A, Powles TS, Browsett C et al. Prediction of response to neoadjuvant chemoendocrine therapy in operable breast. Clinical Cancer Res 1997; 3: 593-600.